

CORPORATE NEWS

Deutsche Biotech Innovativ AG: AGM approves bonus shares and capital increase

Hennigsdorf, 24 July 2015 – The Annual General Meeting of Deutsche Biotech Innovativ AG ("DBI"), which was held in Berlin yesterday, has approved all resolutions proposed by the Management Board and the Supervisory Board of the company with 100 percent. Overall, 98.91 percent of the share capital of the Company were represented.

In particular, the shareholders approved the issue of bonus shares by a capital increase from company funds in the ratio 1:1. Thus, by issuing 447,300 new shares the share capital of the Company will double from currently EUR 447,300.00 to EUR 894,600.00, divided into 894,600 no-par value bearer shares.

In addition, the Annual General Meeting resolved a capital increase against cash contributions by issuing up to 596,400 new shares. The subscription price will be determined later and the shares will be offered to the shareholders for a period of at least two weeks. Any shares not subscribed after the end of the subscription period may be offered to the shareholders and/or interested investors for subscription or purchase. The Management Board was authorized to determine with the approval of the Supervisory Board the further details of the capital increase. This capital increase is expected to be carried out in the second half of 2015.

With the funds generated from the capital increase DBI plans to advance its drug development. This includes in particular the execution of Phase I and II clinical trials with the "First-in-Class" sepsis drug Adrecizumab and the finalization of the pre-clinical studies for the drug DB1RA for prevention of breast cancer.

"We at DBI develop drugs for unmet medical needs. The funds from the capital increase shall allow us to build up and expand our drug pipeline in the future furthermore," says Dr. Bernd Wegener, CEO of DBI.

About Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG ("DBI") is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. The focus of the R&D is on drugs for sepsis and cancer. The company's main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a phase I study starting in 2015.

DBI aims to further expand its drug pipeline and invests in the research and development of drugs that possess a high unique selling point potential.

The members of the DBI Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have long-standing experience in the biotechnology field. Both were part of the founders' and management team of B.R.A.H.M.S. AG, a very successful biotechnology company specializing in the development of blood biomarker for diagnosis and therapy treatment of serious diseases, which was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).

For further information please contact:

Deutsche Biotech Innovativ AG
Susanne Wallace
Tel.: +49 (0)3302 20 77 811
E-mail: s.wallace@dbi-ag.de

Kirchhoff Consult AG
Anja Ben Lekhal
Tel.: +49 (0)40 609 186 55
E-mail: anja.benlekhall@kirchhoff.de

published:

<http://www.dgap.de/dgap/News/corporate/deutsche-biotech-innovativ-agm-approves-bonus-shares-and-capital-increase/?companyID=363635&newsID=889201>